874-23-7Relevant articles and documents
Pyridone derivative and application thereof in preparation of medicine for preventing and/or treating tuberculosis caused by Mycobacterium tuberculosis
-
, (2021/07/01)
The invention provides a pyridone derivative and application thereof in preparation of a medicine for preventing and/or treating tuberculosis caused by mycobacterium tuberculosis, which belong to the field of pharmacy. The structure of the pyridone derivative is shown as a formula (I). Experimental results show that the pyridone derivative provided by the invention can specifically inhibit the activity of mycobacterium tuberculosis, has small toxic and side effects, can be used for preparing a medicine for resisting mycobacterium tuberculosis, can also be used for preparing a medicine for preventing and/or treating tuberculosis, and a new choice is provided for medicines for treating tuberculosis (especially drug-resistant tuberculosis).
Discovery of quinolone derivatives as antimycobacterial agents
Gao, Chao,Li, Xiao,Liu, Kun-Lin,Teng, Fei,Xiong, Lu,Yu, Luo-Ting
, p. 24095 - 24115 (2021/07/29)
Tuberculosis (TB), an infectious disease caused byMycobacterium tuberculosis(M. tuberculosis), is an important public health issue. Current first-line drugs administered to TB patients have been in use for over 40 years, whereas second-line drugs display strong side effects and poor compliance. Additionally, designing effective regimens to treat patients infected with multi- and extremely-drug-resistant (MDR and XDR) strains of TB is challenging. In this report, we screened our compound library and identified compound1with antituberculosis activity and a minimal inhibitory concentration (MIC) againstM. tuberculosisof 20 μg mL?1. Structure optimization and the structure-activity relationship of1as the lead compound enabled the design and synthesis of a series of quinolone derivatives,6a1-6a2,6b1-6b36,6c1,6d1-6d14,7a1-7a2,7b1-7b2,7c1,8a1-8a5,9a1-9a4and10a1-10a6. These compounds were evaluatedin vitrofor anti-tubercular activity against theM. tuberculosisH37Rv strain. Among them, compounds6b6,6b12and6b21exhibited MIC values in the range of 1.2-3 μg mL?1and showed excellent activity against the tested MDR-TB strain (MIC: 3, 2.9 and 0.9 μg mL?1, respectively). All three compounds were non-toxic toward A549 and Vero cells (>100 and >50 μg mL?1, respectively). In addition, an antibacterial spectrum test carried out using compound6b21showed that this compound specifically inhibitsM. tuberculosis. These can serve as a new starting point for the development of anti-TB agents with therapeutic potential.
One-pot method for preparation of 2-acetyl cyclohexanone
-
Paragraph 0009; 0024-0027, (2017/05/27)
The invention discloses a one-pot method for preparation of 2-acetyl cyclohexanone. The method comprises the steps of: (1) adding cyclohexanone into tetrahydrofuran, under the condition of icewater bath cooling, adding lithium diisopropylamide dropwise, and then carrying out stirring reaction at room temperature for 1h; (2) under the condition of icewater bath, adding a trichloromethane solution of acetyl chloride into the reaction system of step (1) dropwise, then removing icewater bath, and carrying out stirring reaction at room temperature for 1h; and (3) washing the reaction solution obtained in step (2) twice and performing liquid separation, conducting spin drying of trichloromethane, then carrying out pressure reduced distillation and collecting 118-136DEG C fractions, thus obtaining 2-acetyl cyclohexanone. According to the method, in the whole reaction process, the intermediate products have no need for additional purification treatment and can be directly subjected to next step reaction, and the finally obtained product is refined directly by pressure reduced distillation. The whole process has the advantages of high yield, short reaction time, and low energy consumption. The 2-acetyl cyclohexanone obtained by direct pressure reduced distillation refining has a concentration of more than 96.0wt%, and the yield is more than 94%.